Category IV indications for therapeutic apheresis - ASFA fourth special issue

Beth H. Shaz; Michael L. Linenberger; Nicholas Bandarenko; Jeffrey L. Winters; Haewon C. Kim; Marisa B. Marques; Ravindra Sarode; Joseph Schwartz; Robert Weinstein; Ashka Wirk; Zbigniew M. Szczepiorkowski

doi:10.1002/jca.20131

Category IV indications for therapeutic apheresis - ASFA fourth special issue

Beth H. Shaz, Michael L. Linenberger, Nicholas Bandarenko, Jeffrey L. Winters, Haewon C. Kim, Marisa B. Marques, Ravindra Sarode, Joseph Schwartz, Robert Weinstein, Ashka Wirk, Zbigniew M. Szczepiorkowski

Research output: Contribution to journal › Review article › peer-review

29 Scopus citations

Abstract

The American Society for Apheresis (ASFA) Committee on Clinical Applications systematically and critically reviews published information on the use of therapeutic apheresis in clinical practice. On the basis of this review, selected diseases are assigned one of five categories (category I, II, III, IV, and P). The diseases, which were classified as category IV indications, and the rationale for such assignment are reviewed in this article. The diseases assigned to category I, II, III, and newly created category P are discussed in a separate article in this issue.

Original language	English (US)
Pages (from-to)	176-180
Number of pages	5
Journal	Journal of Clinical Apheresis
Volume	22
Issue number	3
DOIs	https://doi.org/10.1002/jca.20131
State	Published - Jun 2007

Keywords

Apheresis
Categories
Immunoadsorption
Leukocytapheresis
Photopheresis
Plasma exchange

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/jca.20131

Cite this

@article{91c33014e04c4c97bbd702f04ca0a6d6,

title = "Category IV indications for therapeutic apheresis - ASFA fourth special issue",

abstract = "The American Society for Apheresis (ASFA) Committee on Clinical Applications systematically and critically reviews published information on the use of therapeutic apheresis in clinical practice. On the basis of this review, selected diseases are assigned one of five categories (category I, II, III, IV, and P). The diseases, which were classified as category IV indications, and the rationale for such assignment are reviewed in this article. The diseases assigned to category I, II, III, and newly created category P are discussed in a separate article in this issue.",

keywords = "Apheresis, Categories, Immunoadsorption, Leukocytapheresis, Photopheresis, Plasma exchange",

author = "Shaz, {Beth H.} and Linenberger, {Michael L.} and Nicholas Bandarenko and Winters, {Jeffrey L.} and Kim, {Haewon C.} and Marques, {Marisa B.} and Ravindra Sarode and Joseph Schwartz and Robert Weinstein and Ashka Wirk and Szczepiorkowski, {Zbigniew M.}",

year = "2007",

month = jun,

doi = "10.1002/jca.20131",

language = "English (US)",

volume = "22",

pages = "176--180",

journal = "Journal of Clinical Apheresis",

issn = "0733-2459",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - Category IV indications for therapeutic apheresis - ASFA fourth special issue

AU - Shaz, Beth H.

AU - Linenberger, Michael L.

AU - Bandarenko, Nicholas

AU - Winters, Jeffrey L.

AU - Kim, Haewon C.

AU - Marques, Marisa B.

AU - Sarode, Ravindra

AU - Schwartz, Joseph

AU - Weinstein, Robert

AU - Wirk, Ashka

AU - Szczepiorkowski, Zbigniew M.

PY - 2007/6

Y1 - 2007/6

N2 - The American Society for Apheresis (ASFA) Committee on Clinical Applications systematically and critically reviews published information on the use of therapeutic apheresis in clinical practice. On the basis of this review, selected diseases are assigned one of five categories (category I, II, III, IV, and P). The diseases, which were classified as category IV indications, and the rationale for such assignment are reviewed in this article. The diseases assigned to category I, II, III, and newly created category P are discussed in a separate article in this issue.

AB - The American Society for Apheresis (ASFA) Committee on Clinical Applications systematically and critically reviews published information on the use of therapeutic apheresis in clinical practice. On the basis of this review, selected diseases are assigned one of five categories (category I, II, III, IV, and P). The diseases, which were classified as category IV indications, and the rationale for such assignment are reviewed in this article. The diseases assigned to category I, II, III, and newly created category P are discussed in a separate article in this issue.

KW - Apheresis

KW - Categories

KW - Immunoadsorption

KW - Leukocytapheresis

KW - Photopheresis

KW - Plasma exchange

UR - http://www.scopus.com/inward/record.url?scp=34347398426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347398426&partnerID=8YFLogxK

U2 - 10.1002/jca.20131

DO - 10.1002/jca.20131

M3 - Review article

C2 - 17377982

AN - SCOPUS:34347398426

SN - 0733-2459

VL - 22

SP - 176

EP - 180

JO - Journal of Clinical Apheresis

JF - Journal of Clinical Apheresis

IS - 3

ER -

Category IV indications for therapeutic apheresis - ASFA fourth special issue

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this